These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8098225)

  • 21. Human gastric carcinoid detected during long-term antiulcer therapy of H2 receptor antagonist and proton pump inhibitor.
    Haga Y; Nakatsura T; Shibata Y; Sameshima H; Nakamura Y; Tanimura M; Ogawa M
    Dig Dis Sci; 1998 Feb; 43(2):253-7. PubMed ID: 9512115
    [No Abstract]   [Full Text] [Related]  

  • 22. [Proton pump inhibitors in the treatment of peptic ulcers resistant to H2-receptor antagonists].
    Asaka M; Kato M; Sato Y; Miyazaki T
    Nihon Rinsho; 1992 Jan; 50(1):104-10. PubMed ID: 1347322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group.
    Asaki S; Sato A; Sakurada H; Takeda T; Hongo M; Toyota T
    J Clin Gastroenterol; 1995; 20 Suppl 2():S56-8. PubMed ID: 7594342
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Helicobacter pylori eradication: modified triple therapy with lansoprazole].
    Müller P; Simon B
    Fortschr Med; 1996 Dec; 114(35-36):497-9. PubMed ID: 9119351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lansoprazole--a new proton pump inhibitor.
    Ahmed W; Ali A; Qureshi H; Zuberi SJ; Shamsi ZU
    J Pak Med Assoc; 1995 May; 45(5):144-5. PubMed ID: 7563582
    [No Abstract]   [Full Text] [Related]  

  • 26. Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole.
    Levine A; Shevah O; Shabat-Sehayek V; Aeed H; Boaz M; Moss SF; Niv Y; Avni Y; Shirin H
    Aliment Pharmacol Ther; 2004 Jul; 20(1):117-22. PubMed ID: 15225178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Do other proton pump blockers have advantages over Antra (omeprazole)?].
    Creutzfeldt W
    Internist (Berl); 1996 Sep; 37(9):936-7. PubMed ID: 8964689
    [No Abstract]   [Full Text] [Related]  

  • 28. [Proton pump blockers and their significance in gastroenterology].
    Dítĕ P; Prásek J
    Vnitr Lek; 1995 Aug; 41(8):549-54. PubMed ID: 7483340
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lansoprazole: an update of its place in the management of acid-related disorders.
    Matheson AJ; Jarvis B
    Drugs; 2001; 61(12):1801-33. PubMed ID: 11693467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Several points that should be noticed during PPI treatment for peptic ulcers in elderly patients].
    Kinoshita Y; Fujishiro H; Amano Y; Adachi K
    Nihon Rinsho; 2002 Aug; 60(8):1606-12. PubMed ID: 12187759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [In vitro susceptibilities of Helicobacter pylori strains from children to proton pump inhibitors and its thioether derivative].
    Taneike I; Tamura Y; Shimizu T; Yamashiro Y; Toyoda S; Yamamoto T
    Kansenshogaku Zasshi; 2000 Jul; 74(7):601-2. PubMed ID: 10965666
    [No Abstract]   [Full Text] [Related]  

  • 32. Is lansoprazole (Prevacid) or omeprazole (Prilosec) more effective in treating erosive esophagitis?
    Kim JD
    J Fam Pract; 2002 Apr; 51(4):384. PubMed ID: 11978268
    [No Abstract]   [Full Text] [Related]  

  • 33. Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
    Langtry HD; Wilde MI
    Drugs; 1997 Sep; 54(3):473-500. PubMed ID: 9279507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Usefulness of proton pump inhibitor (PPI) maintenance therapy for patients with H. pylori-negative recurrent peptic ulcer after eradication therapy for H. pylori: pathophysiological characteristics of H. pylori-negative recurrent ulcer scars and beyond acid suppression by PPI.
    Ohara T; Morishita T; Suzuki H; Masaoka T; Ishii H
    Hepatogastroenterology; 2004; 51(56):338-42. PubMed ID: 15086153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of lansoprazole against peptic ulcers induced by non-steroidal anti-inflammatory drugs: endoscopic evaluation of ulcer healing.
    Matsukawa Y; Tomita Y; Nishinarita S; Horie T; Kato K; Arakawa Y; Ko K; Shimada H; Nakano M; Kitami Y; Kurosaka H
    J Int Med Res; 1997; 25(4):190-5. PubMed ID: 9283991
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Eradication rate and side effect from a point of view of Helicobacter pylori eradication of peptic ulcer disease in dual therapy or new triple therapy].
    Iwasaki A
    Nihon Rinsho; 1999 Jan; 57(1):127-33. PubMed ID: 10036949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial.
    Chey WD; Fisher L; Elta GH; Barnett JL; Nostrant T; DelValle J; Hasler WL; Scheiman JM
    Am J Gastroenterol; 1997 Sep; 92(9):1483-6. PubMed ID: 9317068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Microcirculation in gastric mucosa as related to its secretory activity in patients with peptic ulcer].
    Shcherbynina MB
    Lik Sprava; 2002; (5-6):24-6. PubMed ID: 12442513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety profile of Lansoprazole: the US clinical trial experience.
    Freston JW; Rose PA; Heller CA; Haber M; Jennings D
    Drug Saf; 1999 Feb; 20(2):195-205. PubMed ID: 10082075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gastroprotective activity of the novel proton pump inhibitor lansoprazole in the rat.
    Morini G; Grandi D; Arcari ML; Bertaccini G
    Gen Pharmacol; 1995 Sep; 26(5):1021-5. PubMed ID: 7557244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.